Efrat Dotan, MD

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Video: Efrat Dotan, MD

Efrat Dotan, MD

Colorectal Cancer Treatment at Fox Chase Cancer Center

GI Service Line

Learn about colorectal cancer treatment at Fox Chase Cancer Center. From diagnosis to treatment to concerns about your family, our team has experience than can help. (9 min.)

Dr. Efrat Dotan


Attending Physician
Assistant Program Director, 
Medical Oncology Fellowship Program

Meet other members of the

Gastrointestinal Cancer Patient Care Team

Clinical Expertise:

GI malignancies


American Board of Internal Medicine,
Board certification in hematology and medical oncology

Medical Education

MD, Technion, Israel Institute of Technology, Bruce Rappaport Faculty of Medicine, cum laude 2002


Chief Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2007;
Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2006


Chief Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA

Honors and Awards

AMGEN fellowship grant 2009;
American College of Physician (ACP): Associate research competition award.

Research Interests

Principle Investigator page

• Clinical trials of novel treatments for gastrointestinal cancers.
• Drug Development
• Clinical trial specific to older cancer patients.


Dr. Dotan On PubMed and My NCBI
  1. Vijayvergia N, Dotan E, Devarajan K, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center Experience. J Geriatr Oncol. 2015; S1879-4068. [Epub ahead of print].
  2. Dotan E, Li T, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. JOP. September 2014 10(5): 308-14.
  3. McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol, August 2014; 32: 2570-2580.
  4. Dotan E, Devarajan K, D’Silva JA, Beck A, Kloth D, Cohen J S, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies among older adults with metastatic colorectal cancer. Clinical Colorectal Cancer. September 2014; 13(3):192-8.
  5. Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55
  6. Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24
  7. Dotan E, Meropol J N, Burtness B, Denlinger C et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer.  A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC340072
  8. Dotan E, Cohen S J. Challenges in the management of stage II colon cancer. Seminars in Oncology Aug 2011; 38(4): 511-20
  9. Dotan E, Cohen S J, Alpaugh K, Meropol N J. Circulating tumor cells: evolving evidence and future challenges. The oncologist, November 2009, 14(11): 1070-1082